{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:21:11Z","timestamp":1793575271130,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BE MOBILE 1","award":["NCT03928704"],"award-info":[{"award-number":["NCT03928704"]}]},{"name":"BE MOBILE 2","award":["NCT03928743"],"award-info":[{"award-number":["NCT03928743"]}]},{"name":"BE MOVING","award":["NCT04436640"],"award-info":[{"award-number":["NCT04436640"]}]},{"name":"Kaity McCafferty Layte"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1\u2009year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients completing week 52 in the phase 3 studies BE MOBILE 1 (nr-axSpA; NCT03928704) and 2 (r-axSpA; NCT03928743) were eligible for an ongoing open-label extension (OLE; NCT04436640). All OLE patients received subcutaneous bimekizumab 160\u2009mg every 4\u2009weeks. Safety outcomes for patients who received \u22651 bimekizumab dose, and efficacy outcomes for all randomized patients, are reported to week 104.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the OLE (weeks 52\u2009\u2212\u2009104), 70.8% (367\/518) of patients reported \u22651 treatment-emergent adverse event (TEAE). Most frequent TEAEs [exposure-adjusted incidence rate per 100 patient-years (EAIR\/100PY)] were SARS-CoV-2 (COVID-19) infection (25.2), nasopharyngitis (11.0) and oral candidiasis (5.4). Fungal infection EAIR\/100PY was 11.8 (majority Candida infections: 6.8; most mild\/moderate, none serious\/systemic). Inflammatory bowel disease and uveitis rates were low; no major adverse cardiovascular events or deaths occurred. TEAE incidence rate was generally similar across weeks 0 \u2013 52 and 52 \u2013 104.<\/jats:p>\n                  <jats:p>At week 104, &amp;gt;50% of randomized patients (N\u2009=\u2009586) achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40); \u223c60% achieved Axial Spondyloarthritis Disease Activity Score (ASDAS) low disease activity (&amp;lt;2.1) and &amp;gt;30% achieved ASDAS inactive disease (&amp;lt;1.3). Bimekizumab demonstrated sustained suppression of MRI inflammation at week 104, with &amp;gt;57% of patients achieving MRI remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The safety profile of bimekizumab remained consistent with prior reports, with no new safety signals identified. 1-year efficacy was sustained to 2\u2009years across patients with nr-axSpA and r-axSpA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf009","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T14:24:15Z","timestamp":1736605455000},"page":"3534-3546","source":"Crossref","is-referenced-by-count":18,"title":["Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University , Portland, OR,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research , Ghent,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-5619","authenticated-orcid":false,"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, University Hospitals , Cleveland, OH,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta , Edmonton, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tomita","sequence":"additional","affiliation":[{"name":"Graduate School of Health Science, Morinomiya University of Medical Science , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huji","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[{"name":"UCB , Monheim am Rhein,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Vaux","sequence":"additional","affiliation":[{"name":"UCB , Slough,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Prajapati","sequence":"additional","affiliation":[{"name":"UCB , Slough,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Manente","sequence":"additional","affiliation":[{"name":"UCB , Braine-l\u2019Alleud,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marten","sequence":"additional","affiliation":[{"name":"UCB , Monheim am Rhein,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S","family":"Gensler","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology, University of California , San Francisco, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"2025071513372663900_keaf009-B1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard-2023-225185","article-title":"Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature","volume":"83","author":"van der Heijde","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B4","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/keaa422","article-title":"Non-radiographic versus radiographic axSpA: what's in a name?","volume":"59","author":"Michelena","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025071513372663900_keaf009-B5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/kead598","article-title":"Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis","volume":"63","author":"Deodhar","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025071513372663900_keaf009-B6","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"2025071513372663900_keaf009-B7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient Burden of Axial Spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2025071513372663900_keaf009-B8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025071513372663900_keaf009-B9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and Safety of Infliximab in Patients with Ankylosing Spondylitis","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025071513372663900_keaf009-B11","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025071513372663900_keaf009-B12","doi-asserted-by":"crossref","first-page":"1191782","DOI":"10.3389\/fimmu.2023.1191782","article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases","volume":"14","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Front Immunol"},{"key":"2025071513372663900_keaf009-B13","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"2025071513372663900_keaf009-B14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025071513372663900_keaf009-B15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2025071513372663900_keaf009-B16","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","article-title":"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5","volume":"133","author":"Huang","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"2025071513372663900_keaf009-B17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: primary Results of a Randomized, Placebo-Controlled Phase III Study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025071513372663900_keaf009-B18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2025071513372663900_keaf009-B20","doi-asserted-by":"crossref","first-page":"e001306","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"2025071513372663900_keaf009-B21","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"2025071513372663900_keaf009-B22","author":"European Medicines Agency (EMA)"},{"key":"2025071513372663900_keaf009-B23","author":"Food and Drug Administration (FDA)","year":"2023"},{"key":"2025071513372663900_keaf009-B24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2024-eular.2196","article-title":"Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension","volume":"83","author":"Deodhar","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial","volume":"89","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025071513372663900_keaf009-B28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"2025071513372663900_keaf009-B29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"2025071513372663900_keaf009-B30","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"2025071513372663900_keaf009-B31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/art.21337","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025071513372663900_keaf009-B32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2022-222747","article-title":"Instrument selection for the ASAS core outcome set for axial spondyloarthritis","volume":"82","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40744-024-00708-8","article-title":"Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025071513372663900_keaf009-B34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/jof3040052","article-title":"The role of IL-17 in protection against mucosal candida infections","volume":"3","author":"Mengesha","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2025071513372663900_keaf009-B35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2025071513372663900_keaf009-B36","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14740338.2021.1960981","article-title":"Gastroenterological safety of IL-17 inhibitors: a systematic literature review","volume":"21","author":"Caron","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"2025071513372663900_keaf009-B38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025071513372663900_keaf009-B39","doi-asserted-by":"crossref","first-page":"e13572","DOI":"10.1111\/eci.13572","article-title":"Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: an update","volume":"51","author":"Hysa","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2025071513372663900_keaf009-B40","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","volume":"83","author":"Brown","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40744-021-00306-y","article-title":"Cross-walk of the assessment of spondyloarthritis international society health index and ankylosing spondylitis quality of life scores in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients","volume":"8","author":"Pike","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025071513372663900_keaf009-B43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B44","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11136-020-02686-0","article-title":"Validation of the ankylosing spondylitis quality of life assessment tool in patients with non-radiographic axial spondyloarthritis","volume":"30","author":"Hoepken","year":"2021","journal-title":"Qual Life Res"},{"key":"2025071513372663900_keaf009-B45","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","article-title":"Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS","volume":"74","author":"Kiltz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025071513372663900_keaf009-B46","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","article-title":"The ASAS-OMERACT core domain set for axial spondyloarthritis","volume":"51","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf009\/61415076\/keaf009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3534\/61415076\/keaf009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3534\/61415076\/keaf009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:37:38Z","timestamp":1752601058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3534\/7951894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf009","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,11]]}}}